PRONATIV 1000 UI Rumanía - rumano - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

pronativ 1000 ui

octapharma (ip) ltd. - combinatii (factori de coagulare) - pulb+solv. pt. sol. perf. - 1000ui - vitamina k si alte hemostatice factori ai coagularii sanguine

Cevenfacta Unión Europea - rumano - EMA (European Medicines Agency)

cevenfacta

laboratoire francais du fractionnement et des biotechnologies - eptacog beta (activated) - hemophilia a; hemophilia b - hemostatice - cevenfacta is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors viii or ix (i. ≥5 bethesda units (bu)); in patients with congenital haemophilia with low titre inhibitors (bu.

PRONATIV 1000 UI Rumanía - rumano - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

pronativ 1000 ui

octapharma pharmazeutika produktionsges m.b.h. - austria - combinatii (bioactive de coagulare) - pulb.+solv. pt. sol. perf. - 1000ui - vitamina k si alte hemostatice factori ai coagularii sanguine

PRONATIV 500 UI Rumanía - rumano - ANMDM (Agenția Națională a Medicamentului și a Dispozitivelor Medicale din România)

pronativ 500 ui

octapharma pharmazeutika prod. ges.m.b.h. - austria - combinatii (bioactive de coagulare) - pulb.+solv. pt. sol. perf. - 500ui - vitamina k si alte hemostatice factori ai coagularii sanguine

Tepmetko Unión Europea - rumano - EMA (European Medicines Agency)

tepmetko

merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Tabrecta Unión Europea - rumano - EMA (European Medicines Agency)

tabrecta

novartis europharm limited  - capmatinib dihydrochloride monohydrate - carcinom, pulmonar non-celulă mică - agenți antineoplazici - tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy.